Drugs / Burixafor
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02478125 Comparator | Jul 2016 → May 2017 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Burixafor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02478125 ↗ |
| Known as | Burixafor hydrobromide | “Burixafor hydrobromide is a potent anti-CXCR4 agent that is in clinical trials.” NCT02478125 ↗ |
| Action | Inhibit | “a potent anti-CXCR4 agent” NCT02478125 ↗ |
| Route | Intravenous | “When Burixafor hydrobromide is given intravenously (IV) alone at a dose of 3.14 mg/kg” NCT02478125 ↗ |
| Target | CXCR4 | “a potent anti-CXCR4 agent” NCT02478125 ↗ |